Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2022.148 | A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants with Mild to Moderate COVID-19 |
Dr. LUK Andrea On Yan 陸安欣 |
| 2022.634 | A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus |
Prof. LUK Andrea On Yan 陸安欣 |
| 2020.689 | ReFineDR: Observational study of Routine ophthalmological examinations of patients included in the 2 Bayer sponsored phase 3 clinical trials FIDELIO and FIGARO to investigate the effect of Finerenone on delaying the progression of Diabetic Retinopathy |
Dr. LUK Andrea On Yan 陸安欣醫生 |
| 2023.314 | A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION | Prof. LUK Andrea On Yan |
| 2023.369 | Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Prof. LUK Andrea On Yan |
| 2021.501 | An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (BIIB098) in Chinese and Caucasian Adult Healthy Participants |
Dr. LUK Andrea On Yan 陸安欣 |
| 2021.164 | Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in patients with diabetic kidney disease. | Dr. LUK Andrea On Yan |
| 2026.588 | A Phase I, Single Dose, Dose-ascending, Pharmacokinetic Study of Semaglutide Nasal Spray (PT002) in Healthy Volunteers | Prof. Luk Andrea On Yan |
| 2026.276 | Population-based target trial emulation to examine the skeletal effects of glucagon-like peptide-1 receptor agonists in individuals with type 2 diabetes |
Prof. LUK Andrea On Yan 陸安欣 |
| 2014.385 | Best practice of holistic care: A case study approach | Dr. LUK Andrew Leung |
| 2025.103 | CQI Project: Enhancing Triage Assessment to Identify Patients Eligible for Nurse-Initiated Water Cooling for Burn Injuries | Mr. LUK Cheuk ho |
| 2025.899 | Development and Validation of the Eligibility Assessment Tool for Molded Puree (EAT-MP) |
Mr. LUK Chun Lam 陸俊霖 |
| 2007.365 | Longitudinal Change in Mental Competence for Treatment Decision in Chinese Older Adults with Congitive Impairment | Dr. LUK Daisy Nga Yan |
| 2023.237 | Clinical Characteristics and Outcomes of Infections due to carbapenem-resistant Enterobacterales in Hong Kong | Dr. LUK Fion Wing Lam |
| 2016.035 | Whole–body vibration training for residents in a care and attention home in Hong Kong and its influence on balance and mobility: a pilot study |
Ms. LUK Ho Yan 陸可欣 |
| 2008.401 | The Effect of Vital Signs Obtained at Prehospital and Emergency Department's Triage Station on Impatient Admission | Miss LUK Joies Ka Yan |
| 2025.824 | Early Differentiation of Necrotizing Fasciitis from Cellulitis by Comparing LRINEC and SIARI Score: A Retrospective Case-Control Study | Mr. LUK Ka Ngo |
| 2009.414 | The effect of visual stimulation on the adult patient | Mr. LUK Kar Yiu |
| 2013.399 | Focused Ultrasound Screening for Precutaneous Dilatational Tracheostomy | Dr. LUK Leona Wing Kun |
| 2008.190 | Efficacy and Safety of Topical Photodynamic Therapy for Actinic Keratosis among Chinese Patients | Dr. LUK Nai Ming |
| 2011.493 | Hand eczema among inhabilitants of a public housing estate in Hong Kong: a self-administered questionnaire survey | Dr Luk Nai Ming |
| 2009.437 | Efficacy of intralesional 5-fluorouracil in treatment of keloid scar : a randomized-control trial | Dr. LUK Nai Ming |
| 2007.318 | Efficacy and Safety of Diphencyprone (DCP) in the Treatment of Extensive Alopecia Areata in Chinese Patient | Dr. LUK Nai Ming |
| 2026.520 | A Phase III, Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin compared with Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients (reAZURE-NAÏVE ASIA) |
Dr. Luk On Yan 陸安欣 |
| 2013.347 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei | Dr. LUK Sally Wai Yin |
| 2014.406 | Effects of thromboelastography-guided transfusion algorithm versus standard clinical practice on post-operative bleeding and blood product use after cardiac surgery: a randomized, controlled trial | Dr. LUK Ting Hin |
| 2005.471 | Infliximab Induction Therapy for Moderate-to Severe Plaque-Type Psoriasis: An Open-Label, Single Arm Observational Study Evaluating the Efficacy of Use In Hong Kong Chinese Patients | Prof. LUK Tommy Nai Ming |
| 2023.551 | Impact of Injury Prevention Program on Ankle stability for ballet dancers | Ms. LUK Tsz Yan |
| 2005.264 | Psychological Distress, Quality of Life and Marital Relationship among Renal Patients Receiving Continuous Ambulatory Peritoneal Dialysis | Ms. LUK Yvonne Pik Shan |
| 2012.439 | Cross Sectional Survey on Advance Care Planning Acceptance & End of Life Care Preferences among community dwelling elderly with complex medical problems and their carers | Dr LUM Chor Ming |
| 2015.247 | Metformin-associated lactic acidosis requiring intensive care in regional hospitals in Hong Kong and predictive factors for mortality | Dr. LUN Chung Tat |
| 2021.246 | an asthma control questionnaire in a regional hospital during covid-19 pandemic | Dr. LUN Chung Tat |
| 2021.245 | A COPD control questionnaire in a regional hospital during covid-19 pandemic | Dr. LUN Chung Tat |
| 2020.411 | A one–year prospective study for intrapleural pressure for thoracentesis | Dr. LUN Chung Tat |
| 2018.407 | Prospective observational cohort study to assess the ability of mechanically-ventilated patients to press buttons on a smartphone application | Miss LUNG Catherine Chi Yan |
| 2009.460 | A study to assess the success rate of ultra-thin colonoscopy versus conventional colonoscopy for the first or rescue colonoscopy for rescue procedures (UTC study) | Dr. LUO Derek |
| 2008.417 | An Asia Pacific Non-Randomized, Open-Label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-Line Therapy in Subjects with KRAS Wild-Type Metastatic Colorectal Cancer (APEC-Study) | Prof. MA Brigette |
| 2023.693 | Perspectives on illness perception and self-management behaviours from patients with non-alcoholic fatty liver disease and healthcare professionals: An exploratory qualitative study | Ms. MA Angel Cho Kan |
| 2024.264 | A nurse-led lifestyle modification intervention for enhancing self-efficacy, illness perception, self-care management and steatosis grade among patients with metabolic dysfunction-associated steatotic liver disease: A pilot randomised controlled trial | Ms. MA Angel Cho Kan |
| 2023.300 | A nurse-led lifestyle modification intervention for enhancing self-efficacy, illness perception, self-care management and steatosis grade among patients with non-alcoholic fatty liver disease: A randomised controlled trial | Ms. MA Angel Cho Kan |
| 2023.372 | Maintenance strategies in patients with metastatic colorectal cancer following first line induction palliative systemic treatment | Prof. MA Brigette |
| 2022.243 | daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) |
Prof. MA Brigette 馬碧如教授 |
| 2022.262 | A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers | Prof. MA Brigette |
| 2012.192 | A pilot case-control study of second or third line treatment with cetuximab-containing chemotherapy in patients with metastatic colorectal cancer who were previously treated with cetuximab-based chemotherapy | Prof. MA Brigette |
| 2009.486 | A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer | Prof. Ma Brigette |
| 2012.118 | Intensification of pre-operative therapy with multi-agent chemotherapy and concurrent chemoradiotherapy prior to total mesorectal excision surgery in patients with high risk rectal cancer | Prof. MA Brigette |
| 2010.604 | Multicenter Phase II Study of MK-2206 in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma | Prof. MA Brigette |
| 2008.091 | Multi-Centre International Study of Capecitabine + Bevacizumab as Adjuvant Treatment of Colorectal Cancer (QUASAR 2) | Associate Professor Ma Brigette |
| 2009.328 | A Phase I, Randomised, multi-centre, open-label study to determine the pharmacokinetics and tolerability of cediranib (RECENTIN | Prof. Ma Brigette |
| 2008.141 | A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer | Prof. MA Brigette |
Page 175 of 288.